Non-Erosive Gastroesophageal Reflux Disease (NERD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Non-Erosive Gastroesophageal Reflux Disease (NERD) Market Outlook

Thelansis’s “Non-Erosive Gastroesophageal Reflux Disease (NERD) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Non-Erosive Gastroesophageal Reflux Disease treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Non-Erosive Gastroesophageal Reflux Disease (NERD) Overview

Non-erosive reflux disease (NERD) represents a specific manifestation within the spectrum of gastroesophageal reflux disease (GERD). It is defined as a subcategory of GERD characterized by the presence of troublesome reflux-related symptoms, all the while showing no signs of mucosal erosions or breaches in the esophagus during routine endoscopy. In clinical practice, patients presenting with reflux symptoms and negative endoscopic findings can be further classified into four categories:

1. Acid-reflux-related NERD (marked by increased acid reflux)
2. Weakly acid-reflux-related NERD (exhibiting weakly acidic reflux with a positive symptom association, indicative of a hypersensitive esophagus)
3. Nonacid-reflux-related NERD (characterized by nonacidic reflux with a positive symptom association)
4. Functional heartburn (where no discernible link exists between symptoms and reflux).

Comparatively, NERD patients tend to experience lower levels of acid reflux than patients suffering from erosive esophagitis and Barrett's esophagus. The differentiation between NERD and erosive esophagitis currently relies on white light endoscopy. At the same time, the distinction between NERD and functional heartburn necessitates pH monitoring, often coupled with impedance measurements to gauge symptom-reflux associations. In general, it is noted that only around 20-30% of NERD patients respond positively to a standard dose of proton pump inhibitors (PPIs).

• In the United States, the estimated prevalence of GERD falls from 18.1% to 27.8%. Approximately half of all adults will report experiencing reflux symptoms at some point. Remarkably, NERD accounts for a significant proportion of all GERD cases, ranging from 50% to 85%.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2023-2033

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: